# Li Chen

> Li Chen is a Series B investor at GF Xinde Investment Management backing Dental and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [GF Xinde Investment Management](https://shizune.co/investors/profile/gf-xinde-investment-management)
- Total investments: 5
- Last investment: May 2026
- Lead investor: 60%
- Last updated: Aug 2026

Li Chen is a Series B investor at GF Xinde Investment Management focused on Dental and Biotechnology. Dr. Li Chen is the partner of GF Xinde

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Dental | 2 | 40% |
| Biotechnology | 2 | 40% |
| Manufacturing | 2 | 40% |
| Medical Device | 2 | 40% |
| Health Care | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 60% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $40M | Series A | May 14, 2026 |  |
| APTBIO | APTBIO was initiated by Shanghai Institutes for Biological Sciences under Chinese Academy of Sciences in 2004, and is mainly engaged in the application of mass spectrometry technology. The so-called mass spectrometry technology is to measure the quality of protein molecules to carry out the identification of protein molecules, the modification ofprotein molecules and the study of protein molecule interactions. |  | Series C | Apr 08, 2024 |  |
| Geneus | Geneus is a developer of gene sequencers and reagents. |  | Series B | Mar 02, 2023 |  |
| Sifary | Sifary provides professional root canal treatment plans and a dental instrument manufacturer. |  | Series B | Jan 09, 2023 |  |
| Eighteeth | Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents. | $14.8M | Series B | Jan 09, 2023 |  |

5 of 5 investments shown.

## Co-investors
- [Motianshi Touzi](https://shizune.co/investors/profile/motianshi-touzi) — VC Fund, 2 deals together
- [Youshuo Venture Capital](https://shizune.co/investors/profile/youshuo-venture-capital) — VC Fund, 2 deals together
- [CSPC Guofang Pioneer Fund](https://shizune.co/investors/profile/cspc-guofang-pioneer-fund) — VC Fund, 1 deal together
- [CSPC Pharmaceutical Group](https://shizune.co/investors/profile/cspc-pharmaceutical-group) — VC Fund, 1 deal together
- [Dean Diagnostics](https://shizune.co/investors/profile/dean-diagnostics-2bdc) — VC Fund, 1 deal together
- [Fortune Venture Capital](https://shizune.co/investors/profile/fortune-venture-capital) — VC Fund, 1 deal together

## About GF Xinde Investment Management

VC Fund · Guangzhou, China

GF Xinde Investment Management Co., Ltd. was established in 2008 through the approval of the China Securities Commission on Direct Investment, with registered capital of RMB 2.3 billion. GF Xinde is one of the leading direct investment brokerages in China. Through a deep understanding of capital markets, known for integrity, professionalservice, and possessing an abundance of industry resources; GF Xinde not only provides strong financial support to investing corporations, but imparts a wealth of advanced management experience and access to a national business network. Supported by the comprehensive strengths of GF Securities, GF Xinde will assist the invested enterprise with establishing a strategic, long-term plan for growth by increasing their management efficiency, building the ideal capital structure, and a strong platform necessary for a successful IPO. All possible types of investments, merger and acquisitions, business, and technical cooperation opportunities will be provided for the invested enterprise. This will ensure the mutual benefits of both the Company and the invested enterprise are financially sound and increase the overall investment value through business synergies.As a direct investment brokerage, GF Xinde provides distinct advantages in regards to investment resources, market research, professional expertise, mergers and acquisitions and IPO experience. As of December 2014, GF Xinde’s accumulated total assets under management exceeded RMB 5 billion, with 16 successful IPOs, ranking first amongst the industry in both scale and number of successful public offerings.Currently, the Company has successfully created a number of diverse management funds: mezzanine funds, merger and acquisition funds, private equity funds, and other investment funds, covering but not limited to a wide range of industries, such as medicine, consumer stocks, and the internet.

2 contacts available at GF Xinde Investment Management.

| Name | Title | Profile |
| --- | --- | --- |
| Li Chen | Partner | https://shizune.co/investors/profile/li-chen-18ca |
| Xiaoying Mai | Investment Director | https://shizune.co/investors/profile/xiaoying-mai |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Li Chen invest in?

Li Chen invests primarily in Dental, Biotechnology and Manufacturing startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Li Chen last invest?

The most recent investment recorded for Li Chen closed in May 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co